What is BDD Pharma?
BDD Pharma operates as a specialized partner for pharmaceutical entities, offering a comprehensive suite of services that span the entire early-stage development lifecycle. Their core competency lies in biopharmaceutics and oral drug formulation, where they leverage over 25 years of industry expertise to reduce development timelines and operational costs. By maintaining a collaborative, client-centric model, the firm ensures that complex drug development projects are managed with precision and technical rigor. Their market position is defined by a unique ability to bridge the gap between initial formulation and clinical validation, making them an indispensable asset in the modern drug discovery ecosystem.
How much funding has BDD Pharma raised?
BDD Pharma has raised a total of $2.5M across 1 funding round:
Other Financing Round
$2.5M
Other Financing Round (2023): $2.5M with participation from Archangels, British Business Bank, and Scottish Enterprise
Key Investors in BDD Pharma
Archangels
A design-oriented firm with a long-standing history of providing professional architectural and strategic services to institutional and commercial clients.
British Business Bank
A government-backed financial institution focused on increasing the supply of credit and providing essential business advisory services to small and medium-sized enterprises.
Scottish Enterprise
The Scottish government's economic development agency, dedicated to fostering innovation and growth within the Scottish business landscape.
What's next for BDD Pharma?
With this major enterprise-level funding, BDD Pharma is well-positioned to scale its operational capacity and further refine its Lean Clinical Development framework. The strategic allocation of these resources will likely focus on expanding their GMP manufacturing capabilities and enhancing their integrated clinical trial support infrastructure. As the pharmaceutical industry continues to prioritize efficiency and speed-to-market, BDD Pharma's commitment to tailored, high-quality research solutions will be critical in maintaining their competitive advantage. Future growth trajectories suggest a continued expansion of their footprint in the global CRO/CDMO market, driven by sustained demand for specialized, early-stage development expertise.
See full BDD Pharma company page
